OR WAIT 15 SECS
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
VIENNA - The ascomycin derivative pimecrolimus (ASM 981, Elidel) - currently in Phase III trials for the treatment of atopic dermatitis (topical) and psoriasis (oral) - exhibits skin-specific anti-inflammatory activity and has low potential for immunosuppression in both its topical and oral formulations.